

U p/c at Baseline and Weeks 3, 4, 8, 12, 24, 30, 36, and 52 Following Conversion to SRL

Statistical Analysis		
Groups	Ramipril	Change from Baseline at Week 3, Ramipril
Non-Inferiority/Equivalence Test	No	
P Value	NOTE: Both P-value and estimated Confidence Interval have not been entered for a statistical analysis.	
Method		
Other Adjusted Geometric Mean Fold Change	1.16	Adjusted for baseline

Statistical Analysis		
Groups	Placebo	Change from Baseline at Week 3, Placebo
Non-Inferiority/Equivalence Test	No	
P Value	NOTE: Both P-value and estimated Confidence Interval have not been entered for a statistical analysis.	
Method		
Other Adjusted Geometric Mean Fold Change	1.36	Adjusted for baseline

Statistical Analysis		
Groups	Ramipril	Change from baseline at Week 4, Ramipril
Non-Inferiority/Equivalence Test	No	
P Value		
Method		
Other Adjusted Geometric Mean Fold Change	1.18	Adjusted for baseline

Statistical Analysis		
Groups	Placebo	Change from baseline at Week 4, Placebo
Non-Inferiority/Equivalence Test	No	
P Value	NOTE: Both P-value and estimated Confidence Interval have not been entered for a statistical analysis.	
Method		
Other Adjusted Geometric Mean Fold Change	1.52	Adjusted for baseline

Statistical Analysis		
Groups	Ramipril	Change from baseline at Week 8, Ramipril
Non-Inferiority/Equivalence Test	No	
P Value	NOTE: Both P-value and estimated Confidence Interval have not been entered for a statistical analysis.	
Method		
Other Adjusted Geometric Mean Fold Change	1.27	Adjusted for baseline

Statistical Analysis		
Groups	Placebo	Change from baseline at Week 8, Placebo
Non-Inferiority/Equivalence Test	No	
P Value	NOTE: Both P-value and estimated Confidence Interval have not been entered for a statistical analysis.	
Method		
Other Adjusted Geometric Mean Fold Change	1.61	Adjusted for baseline

Statistical Analysis		
Groups	Ramipril	Change from Baseline at Week 12, Ramipril
Non-Inferiority/Equivalence Test	No	
P Value	NOTE: Both P-value and estimated Confidence Interval have not been entered for a statistical analysis.	
Method		
Other Adjusted Geometric Mean Fold Change	1.34	Adjusted for baseline

Statistical Analysis		
Groups	Placebo	Change from Baseline at Week 12, Placebo
Non-Inferiority/Equivalence Test	No	
P Value	NOTE: Both P-value and estimated Confidence Interval have not been entered for a statistical analysis.	
Method		
Other Adjusted Geometric Mean Fold Change	1.63	Adjusted for baseline

Statistical Analysis		
Groups	Ramipril	Change from Baseline at Week 24, Ramipril
Non-Inferiority/Equivalence Test	No	
P Value	NOTE: Both P-value and estimated Confidence Interval have not been entered for a statistical analysis.	
Method		
Other Adjusted Geometric Mean Fold Change	1.48	Adjusted for baseline

Statistical Analysis		
Groups	Placebo	Change from Baseline at Week 24, Placebo
Non-Inferiority/Equivalence Test	No	
P Value	NOTE: Both P-value and estimated Confidence Interval have not been entered for a statistical analysis.	
Method		
Other Adjusted Geometric Mean Fold Change	1.78	Adjusted for baseline

Statistical Analysis		
Groups	Ramipril	Change from Baseline at Week 30, Ramipril
Non-Inferiority/Equivalence Test	No	
P Value	NOTE: Both P-value and estimated Confidence Interval have not been entered for a statistical analysis.	
Method		
Other Adjusted Geometric Mean Fold Change	1.43	Adjusted for baseline

Statistical Analysis		
Groups	Placebo	Change from Baseline at Week 30, Placebo
Non-Inferiority/Equivalence Test	No	
P Value	NOTE: Both P-value and estimated Confidence Interval have not been entered for a statistical analysis.	
Method		
Other Adjusted Geometric Mean Fold Change	1.82	Adjusted for baseline

Statistical Analysis		
Groups	Ramipril	Change from Baseline at Week 36, Ramipril
Non-Inferiority/Equivalence Test	No	
P Value	NOTE: Both P-value and estimated Confidence Interval have not been entered for a statistical analysis.	
Method		
Other Adjusted Geometric Mean Fold Change	1.40	Adjusted for baseline

Statistical Analysis		
Groups	Placebo	Change from Baseline at Week 36, Placebo
Non-Inferiority/Equivalence Test	No	
P Value	NOTE: Both P-value and estimated Confidence Interval have not been entered for a statistical analysis.	
Method		
Other Adjusted Geometric Mean Fold Change	1.67	Adjusted for baseline

Statistical Analysis		
Groups	Ramipril	Change from Baseline at Week 52, Ramipril
Non-Inferiority/Equivalence Test	No	
P Value	NOTE: Both P-value and estimated Confidence Interval have not been entered for a statistical analysis.	
Method		
Other Adjusted Geometric Mean Fold Change	1.56	Adjusted for baseline

Statistical Analysis		
Groups	Placebo	Change from Baseline at Week 52, Placebo
Non-Inferiority/Equivalence Test	No	
P Value	NOTE: Both P-value and estimated Confidence Interval have not been entered for a statistical analysis.	
Method		
Other Adjusted Geometric Mean Fold Change	1.86	Adjusted for baseline